Company intelligence / Profile preview
ReNewVax Ltd
Liverpool, England, United Kingdomrenewvax.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Preclinical
01
Overview
ReNewVax’s lead candidate RVX‑001 is a protein-based universal pneumococcal vaccine that has demonstrated protection against all tested strains in murine models. The technology offers lower manufacturing costs compared to existing vaccines. Preclinical proof-of-concept has been established; first-in-human trials are planned for 2025. The company aims to address the limitations of current pneumococcal vaccines by providing broader coverage and supporting efforts against antimicrobial resistance.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Protein-based vaccinesRational vaccine design using genomic analysis and ex vivo human predictive models
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on ReNewVax Ltd.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReNewVax Ltd.